Tango Therapeutics Q1 net loss $0.32/sh; cash $334M funds pipeline into 2026

Tango Therapeutics, Inc.

2023-Q1 EPS reported -$0.32 revenue$5,766,000

Q1 net loss $28.0M ($0.32 per share) vs $25.2M ($0.29) in prior year; revenue flat at $5.8M.
Cash and equivalents $333.6M; expects to fund operations into 2026.
TNG908 shows proof-of-mechanism with selective PRMT5 inhibition in MTAP-deleted tumors; no DLTs or grade >2 AEs.
FDA cleared IND for TNG260 (CoREST inhibitor) and granted Fast Track designation for STK11-mutant NSCLC; phase 1/2 to start 2H 2023.
Appointed Adam Crystal, M.D., Ph.D., as President of R&D in February 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Tango Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023.

Period: the first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2023, and provided business highlights.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Tango Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-019133

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.